Pathios Therapeutics Welcomes Dr. Jon Wigginton to Board
Internationally recognized for his expertise in immuno-oncology drug development, Dr. Jon Wigginton brings nearly three decades of experience in clinical oncology to the board of Pathios Therapeutics Limited. The company, a pioneer in advancing the first clinical GPR65 antagonist program for cancer therapy, is excited to leverage Dr. Wigginton's extensive background.
As the current President of Research and Development at Bright Peak Therapeutics, Dr. Wigginton oversees the advancement of novel PD-1 inhibitors in the immuno-oncology arena. His prior role as Senior Advisor and Chairman of the Scientific Advisory Board at Cullinan Oncology provided him with a rich foundation to guide innovative strategies in cancer treatment. His leadership as Chief Medical Officer at MacroGenics further solidified his reputation within the pharmaceutical and biopharmaceutical sectors.
Dr. Wigginton's notable tenure includes significant contributions at Bristol Myers Squibb (BMS) where he served as the Executive Director for Immuno-Oncology Early Clinical Research. Here, he was instrumental in the development of a range of therapies, including the widely recognized checkpoint inhibitors. His work at BMS helped establish the company among the leaders in immuno-oncology through trials that reshaped the landscape of cancer treatment.
Expressing enthusiasm about joining Pathios, Dr. Wigginton stated, "The tremendous team at Pathios and its innovative approach to combating cancer present exciting opportunities. I'm eager to contribute to the development of PTT-4256 and support the team in expanding their groundbreaking work." This enthusiasm aligns with Pathios' mission to combat the challenges faced in current cancer therapies.
Pathios Therapeutics is committed to pioneering a first-of-its-kind therapeutic strategy by targeting GPR65, a G protein-coupled receptor that has been identified as pivotal in cancer immunity. The lead program, PTT-4256, represents a novel approach to treating cancer by counteracting the immunosuppressive mechanisms that solid tumors exploit. By antagonizing GPR65, PTT-4256 has demonstrated significant potential to enhance immune system activity against tumors.
The significance of GPR65 in the tumor microenvironment has been highlighted through internal human genetic analyses. Insights suggest that lower GPR65 function correlates with improved survival rates across various solid tumor types, positioning this receptor as a potent target for therapeutic interventions.
With promising preclinical data showcasing excellent drug-like properties and anti-tumor activity, Pathios is currently enrolling patients for the RAISIC-1 trial, which aims to assess PTT-4256's effectiveness in a broad range of advanced solid tumors.
About Pathios Therapeutics
Pathios is dedicated to translating innovative scientific discoveries into effective medicines. Founded by seasoned professionals from the biotech and pharmaceutical sectors, Pathios focuses on developing small molecule antagonists targeting GPR65 to mitigate the immunosuppressive effects on immune cells. The company has successfully raised substantial funding, indicating strong investor confidence and strategic interest.
Pathios operates from its headquarters in Milton Park, participating in a dynamic drug discovery ecosystem. As a member of the Molecule to Medicine initiative, Pathios is poised to make significant contributions to the field of immuno-oncology.
Contact Information
Pathios Therapeutics
Paul Higham, CEO
+44 1235 644 960
Tom McCarthy, Executive Chair
+44 1235 644 960
Tim Brons, Vida Strategic Partners
+1 646 319 8981
Frequently Asked Questions
What is the role of Dr. Jon Wigginton at Pathios Therapeutics?
Dr. Jon Wigginton has been appointed as a non-executive director, bringing his extensive experience in immuno-oncology to guide the company.
What is PTT-4256?
PTT-4256 is a clinical-stage oral small molecule GPR65 antagonist developed by Pathios Therapeutics, targeting immunosuppressive mechanisms in tumors.
What therapeutic approach does Pathios Therapeutics pursue?
Pathios Therapeutics focuses on GPR65 antagonism to enhance immune response against cancers, aiming to advance innovative treatment strategies.
What is the RAISIC-1 trial?
The RAISIC-1 trial is a Phase 1/2 study evaluating the efficacy of PTT-4256 in patients with advanced solid tumors.
Where is Pathios Therapeutics located?
Pathios is headquartered in Milton Park, a prominent science precinct near Oxford, UK, involved in the Molecule to Medicine drug discovery initiative.
